Furthermore to these presentations at the FDA, a lot more than 60 researchers have presented their research using Caliper’s technologies this year at user meetings attended by more than 600 current and potential customers.. Caliper Existence Sciences presents the advantages of its LabChip GX platform Caliper Existence Sciences, Inc. , a leading provider of existence sciences tools, presented at a training program for reviewers from america Food and Drug Administration on the advantages of the LabChip GX platform for high throughput screening and characterization assays for biological medicines. ‘We were very happy to accept the FDA’s invitation to present our LabChip platform to a large group of reviewers. We believe the LabChip system will accelerate the adoption of quality-by-design techniques that ultimately will enhance the safety profiles of brand-new biologics and vaccines,’ said Kevin Hrusovsky, CEO of Caliper Lifestyle Sciences.In arm A, the entire response price was 42 percent , including 7 percent of individuals achieving a very good partial response and 2 percent achieving a complete response . In arm B, the ORR was 39 percent with 5 percent of patients achieving a VGPR no sufferers achieving a CR. The median durations of response were 119 days and 126 days in hands A and B, respectively. Median event-free survival moments were 219 and 152 days for arms A and B, respectively. Toxicity consisted of myelosuppression in both arms primarily. The occurrence of neuropathy, worsening of pre-existing neuropathy or thromboembolic occasions was not observed. Abstract #863 – Pomalidomide Plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Evaluation of Two Dosing Strategies in Dual-Refractory Disease In a Phase 2 study shown by Martha Lacy, M.D., of the Mayo Clinic, two different doses of pomalidomide with low dosage dexamethasone 40 mg were studied.